One literature showed that inhibition of intestinal FXR or FXR deficiency could promote glucagon-likepeptide-1 (GLP-1) secretion thus improving obesity-induced glucose intolerance and insulin resistance (Sun et al., 2018). This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.